An interventional study of Active Music Engagement and Audio Storybooks in Acute Lymphoblastic Leukemia, Pediatric and Pediatric Cancer, sponsored by Indiana University. Completed at 4 sites in United States. Open to participants aged 3 Years to 8 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Indiana University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 168 open to participants now, 274 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 110th largest by enrollment of the 1,269 interventional ones that give a count, is one of 36 that started in 2020, is one of 186 with no phase, and was the 1,292nd registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →168 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Wake Forest University Health Sciences · Sites in United States
Ages 18+
St. Jude Children's Research Hospital · Sites in United States
Ages 8+ · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States
Ages 1–25
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 3 Years to 8 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,545 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 653 · Phase 2 593 · Phase 3 107 · Phase 4 10
First in 1984; this study’s year is marked. 36 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 35 across the 1,269 interventional studies, 110 across the 154 observational. Of the 1,181 that completed or were terminated, 438 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 1,545 have an industry lead sponsor. The 10 most frequent:
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
Indiana University has 4 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
95 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03020030Phase 3Dana-Farber Cancer InstituteTreatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | 2026-11-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04851717Phase 3Acacia Pharma LtdInvestigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | 2027-10 |
| NCT03104491Leland MethenyInotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
Add all 95 to your calendar (.ics) → With an account.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Music therapy has become a standard palliative care service in many pediatric and adult hospitals; however, a majority of music therapy research has focused on the use of music to improve psychosocial dimensions of health, without considering biological dimensions. This study builds on prior work examining the psychosocial mechanisms of action underlying an Active Music Engagement (AME) intervention, designed to help manage emotional distress and improve positive health outcomes in young children with cancer and parents, by examining its effects on biomarkers of stress and immune function. The purposes of this two group, randomized controlled trial are to examine biological mechanisms of effect and dose-response relationships of AME on child/parent stress during the consolidation phase of Acute Lymphoblastic Leukemia (ALL) treatment. Specific aims are to: Aim 1. Establish whether AME lowers child and parent cortisol during ALL treatment. Aim 2. Examine cortisol as a mediator of AME effects on child and parent outcomes during ALL treatment. Aim 3 (exploratory). Examine the dose-response relationship of AME on child and parent cortisol during ALL treatment. Findings will provide a more holistic understanding about how active music interventions work to mitigate cancer-related stress and its potential to improve immune function, with direct implications for the evidence-based use of music to improve health.
Music therapy has become a standard palliative care service in many pediatric and adult hospitals. However, a majority of music therapy research has focused on the use of music to improve psychosocial dimensions of health, without considering biological dimensions. In addition, few studies have examined dose-response relationships. Cancer treatment is an inherently stressful experience, and a significant number of young children and parents (caregivers) experience persistent, interrelated emotional distress and poor quality of life. Many parents also experience traumatic stress symptoms because of their child's cancer diagnosis and treatment. The investigators previously tested an Active Music Engagement (AME) intervention that uses active music play to diminish stressful attributes of cancer treatment to help manage emotional/traumatic distress experienced by young children (ages 3-8) and parents and improve quality of life. A recent AME trial is examining psychosocial mechanisms of action responsible for change in child/parent outcomes. The current study expands on this work by examining AME's effects on several biomarkers to provide a more holistic understanding about how active music interventions work to mitigate cancer-related stress and its potential to improve immune function. The purposes of this two group, randomized controlled trial are to examine biological mechanisms of effect and dose-response relationships of AME on child/parent stress during the consolidation phase of Acute Lymphoblastic Leukemia (ALL) treatment. Specific aims are to: 1) establish whether AME lowers child and parent cortisol, 2) examine cortisol as a mediator of AME effects on child and parent outcomes, and 3) examine the dose-response relationship of AME on child and parent cortisol. Child/parent dyads (n=250) will be stratified (by age, site, ALL risk level) and randomized in blocks of four to AME or attention control. Each group will receive one 45-minute session during weekly clinic visits for the duration of ALL consolidation (4 weeks standard risk; 8 weeks high risk). Parents will complete measures at baseline and following the last study session. Child and parent salivary cortisol samples will be taken pre and post-session for the first 4 AME or attention control sessions. Child blood samples will be reserved from routine blood draws prior to sessions 1 and 4 (all participants) and session 8 (high risk participants). Linear mixed models will be used to estimate AME's effect on child and parent cortisol. Examining child and parent cortisol as mediators of AME effects on child and parent outcomes will be performed in an ANCOVA setting, fitting the appropriate mediation models using MPlus and then testing indirect effects using the percentile bootstrap approach to estimate the indirect effect. Graphical plots and non-linear repeated measures models will be used to examine the dose-response relationship of AME on child and parent cortisol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
See intervention description.
Behavioral: Active Music Engagement
See intervention description.
Behavioral: Audio Storybooks
Weekly 30-minute sessions with a board-certified music therapist delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. During the first visit, parent and child will receive information on how they can use music play activities to help manage distress during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During subsequent visits the music therapist will lead parent and child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
Weekly 30-minute sessions with a trained provider delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. Each session children/parents will choose and listen to one of three illustrated children's books with audio-recorded narration.
Percent Change in Child Stress (Salivary Cortisol)
The primary outcome will be the percent change in child salivary cortisol from pre- to post-session at each session number (2, 3 and 4) for each child. This outcome will be calculated as 100\*ln(post/pre) to represent the percentage change in cortisol levels (ln=natural logarithm function). Negative values will indicate a reduction in cortisol relative to the pre-session value. Investigators will use a linear mixed effects model for repeated measures to examine change in the cortisol levels over time with child as a subject effect. Predictors will include session number (2, 3, 4), intervention group (AME vs Storybooks) and patient risk level (High vs Standard). A variety of covariance structures will be examined and one will be chosen exhibiting the smallest Akaike's Information Criterion (AIC) value.
Time frame: Pre/Post-Sessions 2, 3, and 4 (each session is 7 days apart; each session has a 30 min. duration).
Percent Change in Parent Stress (Salivary Cortisol)
The primary outcome will be the percent change in parent salivary cortisol from pre- to post-session at each session number (1, 2, 3 and 4) for each parent. This outcome will be calculated as 100\*ln(post/pre) to represent the percentage change in cortisol levels (ln=natural logarithm function). Negative values will indicate a reduction in cortisol relative to the pre-session value. Investigators will use a linear mixed effects model for repeated measures to examine change in the cortisol levels over time with parent as a subject effect. Predictors will include session number (1, 2, 3, 4), intervention group (AME vs Storybooks) and patient risk level (High vs Standard). A variety of covariance structures will be examined and one will be chosen exhibiting the smallest Akaike's Information Criterion (AIC) value.
Time frame: Pre/Post-Sessions 1, 2, 3, and 4 (each session is 7 days apart; each session has a 30 min. duration).
Change in Child Immune Function - IL-10 Cytokine
IL-10 is a cytokine broadly produced by many cells in the immune system. It is a feedback regulator known to limit inflammatory responses. IL-10 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (6.9 pg/mL) was assigned.
Time frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
Change in Child Immune Function - IL-13 Cytokine
IL-13 is a cytokine that helps drive type 2 responses allowing the body to defend against parasites by activating mast cells, basophils, and eosinophils. IL-13 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (1.9 pg/mL) was assigned.
Time frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
Change in Child Immune Function - IL-6 Cytokine
IL- 6 is a pro-inflammatory cytokine that activates the JAK/STAT pathway. IL-6 is part of defense against infections; however, overproduction can lead to severe complications. IL-6 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (1.4 pg/mL) was assigned.
Time frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
Change in Child Immune Function - TNF-α Cytokine
TNF-α is a pro-inflammatory cytokine known activate innate and adaptive immune responses. The chemical signals from TNF will affect the body's response to infection. TNF-α was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (26.7 pg/mL) was assigned.
Time frame: Pre-session 1 (all children); Pre-Session 4 (all children); Pre-Session 8 (high risk children only)
Percent Change in Salivary Cortisol and Child Health Questionnaire-Mental Health Subscale (CHQ)
Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child mental health through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. CHQ mental health scores range from 16 - 80 with higher scores indicating better mental health. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.
Time frame: Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
Percent Change in Salivary Cortisol and KINDLR Questionnaire for Measuring Health-Related Quality of Life in Children
Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child quality of life through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. KINDLR quality of life scores range from 20 - 100 with higher scores indicating better quality of life. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.
Time frame: Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
Percent Change in Salivary Cortisol and Profile of Mood States - Short Form (POMS-SF)
Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's mood disturbance through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. POMS-SF scores range from -32-116 with higher scores indicating greater mood disturbance. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.
Time frame: Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
Percent Change in Salivary Cortisol and Impact of Events Scale - Revised (IES-R)
Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's traumatic stress symptoms through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. IES-R scores range from 0-12 with higher scores indicating greater traumatic stress symptoms. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.
Time frame: Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
Percent Change in Salivary Cortisol and Index of Well-being
Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's well-being through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. IWB scores range from 9-63 with higher scores indicating greater well-being. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.
Time frame: Baseline; Follow-up Post-Session Week 4 (standard risk participants); Follow-up Post-Session Week 8 (high risk participants)
| Milestone | Active Music Engagement - Children | Active Music Engagement - Parents | Audio Storybooks - Children | Audio Storybooks - Parents |
|---|---|---|---|---|
| Started | 46 | 46 | 47 | 47 |
| Completed | 44 | 44 | 44 | 44 |
| Not completed | 2 | 2 | 3 | 3 |
The primary outcome will be the percent change in child salivary cortisol from pre- to post-session at each session number (2, 3 and 4) for each child. This outcome will be calculated as 100\*ln(post/pre) to represent the percentage change in cortisol levels (ln=natural logarithm function). Negative values will indicate a reduction in cortisol relative to the pre-session value. Investigators will use a linear mixed effects model for repeated measures to examine change in the cortisol levels over time with child as a subject effect. Predictors will include session number (2, 3, 4), intervention group (AME vs Storybooks) and patient risk level (High vs Standard). A variety of covariance structures will be examined and one will be chosen exhibiting the smallest Akaike's Information Criterion (AIC) value.
| pre to post ln(%) change across sessions | Active Music Engagement (Child) | Audio Storybooks (Child) |
|---|---|---|
| Percent Change in Child Stress (Salivary Cortisol) | -33.28 ± 6.95 | -7.82 ± 8.12 |
The primary outcome will be the percent change in parent salivary cortisol from pre- to post-session at each session number (1, 2, 3 and 4) for each parent. This outcome will be calculated as 100\*ln(post/pre) to represent the percentage change in cortisol levels (ln=natural logarithm function). Negative values will indicate a reduction in cortisol relative to the pre-session value. Investigators will use a linear mixed effects model for repeated measures to examine change in the cortisol levels over time with parent as a subject effect. Predictors will include session number (1, 2, 3, 4), intervention group (AME vs Storybooks) and patient risk level (High vs Standard). A variety of covariance structures will be examined and one will be chosen exhibiting the smallest Akaike's Information Criterion (AIC) value.
| pre to post ln(%) change across sessions | Active Music Engagement (Parent) | Audio Storybooks (Parent) |
|---|---|---|
| Percent Change in Parent Stress (Salivary Cortisol) | -33.71 ± 5.42 | -15.33 ± 5.60 |
IL-10 is a cytokine broadly produced by many cells in the immune system. It is a feedback regulator known to limit inflammatory responses. IL-10 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (6.9 pg/mL) was assigned.
| pg/mL | Active Music Engagement (Child) | Audio Storybooks (Child) |
|---|---|---|
| Pre-session 1 | 6.9 ± 0.0 | 7.4 ± 2.6 |
| Pre-session 4 | 7.1 ± 1.1 | 6.9 ± 0.5 |
| Pre-session 8 | 6.9 ± 0.0 | 6.9 ± 0.0 |
IL-13 is a cytokine that helps drive type 2 responses allowing the body to defend against parasites by activating mast cells, basophils, and eosinophils. IL-13 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (1.9 pg/mL) was assigned.
| pg/mL | Active Music Engagement (Child) | Audio Storybooks (Child) |
|---|---|---|
| Pre-session 1 | 1.9 ± 0.1 | 1.9 ± 0.0 |
| Pre-session 4 | 1.9 ± 0.0 | 1.9 ± 0.0 |
| Pre-session 8 | 1.9 ± 0.0 | 1.9 ± 0.0 |
IL- 6 is a pro-inflammatory cytokine that activates the JAK/STAT pathway. IL-6 is part of defense against infections; however, overproduction can lead to severe complications. IL-6 was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (1.4 pg/mL) was assigned.
| pg/mL | Active Music Engagement (Child) | Audio Storybooks (Child) |
|---|---|---|
| Pre-session 1 | 1.5 ± 0.1 | 1.5 ± 0.1 |
| Pre-session 4 | 1.9 ± 2.1 | 6.5 ± 29.8 |
| Pre-session 8 | 1.6 ± 0.5 | 1.9 ± 1.5 |
TNF-α is a pro-inflammatory cytokine known activate innate and adaptive immune responses. The chemical signals from TNF will affect the body's response to infection. TNF-α was measured using the BioRad BioPlex Human 7-plex assay. This assay uses antibodies to detect and quantify cytokine levels. Most assay values were below the limit of detection (LOD). For all participants with values below the LOD, the lowest non-zero calibrator (26.7 pg/mL) was assigned.
| pg/mL | Active Music Engagement (Child) | Audio Storybooks (Child) |
|---|---|---|
| Pre-session 1 | 27.6 ± 5.3 | 27.7 ± 4.9 |
| Pre-session 4 | 27.3 ± 4.2 | 30.2 ± 20.1 |
| Pre-session 8 | 26.7 ± 0.0 | 26.7 ± 0.0 |
Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child mental health through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. CHQ mental health scores range from 16 - 80 with higher scores indicating better mental health. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.
| score on a scale | Active Music Engagement | Audio Storybooks |
|---|---|---|
| Baseline | 41.9 ± 16.9 | 43.3 ± 14.6 |
| Follow-up | 27.4 ± 14.0 | 28.6 ± 15.4 |
Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child quality of life through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. KINDLR quality of life scores range from 20 - 100 with higher scores indicating better quality of life. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.
| score on a scale | Active Music Engagement | Audio Storybooks |
|---|---|---|
| Baseline | 57.4 ± 18.1 | 56.3 ± 17.7 |
| Follow-up | 71.0 ± 14.9 | 70.7 ± 12.8 |
Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's mood disturbance through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. POMS-SF scores range from -32-116 with higher scores indicating greater mood disturbance. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.
| score on a scale | Active Music Engagement | Audio Storybooks |
|---|---|---|
| Baseline | 53.4 ± 23.8 | 65.4 ± 27.4 |
| Follow-up | 42.8 ± 22.1 | 50.2 ± 26.1 |
Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's traumatic stress symptoms through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. IES-R scores range from 0-12 with higher scores indicating greater traumatic stress symptoms. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.
| score on a scale | Active Music Engagement | Audio Storybooks |
|---|---|---|
| Baseline | 3.4 ± 2.0 | 4.0 ± 2.1 |
| Follow-up | 2.5 ± 1.9 | 3.2 ± 1.9 |
Using Mplus software, investigators will conduct a parallel mediation analysis within a structural equation modeling (SEM) framework to evaluate the mechanisms of the intervention. The model will simultaneously test two indirect effects (a\*b): (1) the intervention's impact on child's well-being through percent change in child cortisol, and (2) the impact through percent change in parent cortisol. IWB scores range from 9-63 with higher scores indicating greater well-being. Mediators will be calculated as an average of pre to post session change in salivary cortisol across sessions for both children and parents. The model will be adjusted for patient risk level (high vs. standard), age, study site and baseline version of outcome as covariates. Percentile bootstrap approach (5,000 resamples) will be used to generate 95% confidence intervals. Missing data will be handled via Full Information Maximum Likelihood (FIML) to ensure robust parameter estimation.
| score on a scale | Active Music Engagement | Audio Storybooks |
|---|---|---|
| Baseline | 47.4 ± 10.1 | 45.3 ± 9.6 |
| Follow-up | 49.8 ± 10.4 | 45.7 ± 9.6 |
Collected over from randomization until end of follow-up, up to 14 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Music Engagement - Child | 0/46 (0%) | 0/46 (0%) | 0/46 (0%) |
| Active Music Engagement - Parent | 0/46 (0%) | 0/46 (0%) | 1/46 (2.2%) |
| Audio Storybooks - Child | 0/47 (0%) | 0/47 (0%) | 1/47 (2.1%) |
| Audio Storybooks - Parent | 0/47 (0%) | 0/47 (0%) | 0/47 (0%) |
| Event | Active Music Engagement - Child | Active Music Engagement - Parent | Audio Storybooks - Child | Audio Storybooks - Parent |
|---|---|---|---|---|
| Parent stressSocial circumstances | 0/46 | 1/46 | 0/47 | 0/47 |
| Child emotional dysregulationSocial circumstances | 0/46 | 0/46 | 1/47 | 0/47 |
| Age, Continuous(Years) | Active Music Engagement (Child) | Active Music Engagement (Parent) | Audio Storybooks (Child) | Audio Storybooks (Parent) | Total |
|---|---|---|---|---|---|
| Mean | 4.5 ± 1.4 | 35.2 ± 5.5 | 4.4 ± 1.5 | 35.1 ± 5.3 | 19.8 ± 15.9 |
| Sex: Female, Male(Participants) | Active Music Engagement (Child) | Active Music Engagement (Parent) | Audio Storybooks (Child) | Audio Storybooks (Parent) | Total |
|---|---|---|---|---|---|
| Female | 19 | 37 | 22 | 38 | 116 |
| Male | 27 | 9 | 24 | 8 | 68 |
| Ethnicity (NIH/OMB)(Participants) | Active Music Engagement (Child) | Active Music Engagement (Parent) | Audio Storybooks (Child) | Audio Storybooks (Parent) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 6 | 5 | 6 | 24 |
| Not Hispanic or Latino | 38 | 39 | 40 | 40 | 157 |
| Unknown or Not Reported | 1 | 1 | 2 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Active Music Engagement (Child) | Active Music Engagement (Parent) | Audio Storybooks (Child) | Audio Storybooks (Parent) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 4 | 2 | 6 |
| Asian | 2 | 2 | 3 | 4 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 4 | 2 | 3 | 13 |
| White | 35 | 35 | 36 | 36 | 142 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 5 | 2 | 2 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Apr 2025, 56 months.
Results were first posted in Oct 2026, 1 year 6 months after primary completion.
Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's 56 months is above that.
Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →